GLP-3 (Retatrutide) and Menopause: What Women Need to Know About the 'Triple Agonist'

If you have spent any time on social media lately, you have probably seen the term. "GLP-3." It shows up in weight-loss forums, in midlife Facebook groups, in the comments under every menopause influencer. Search interest in "GLP-3 peptide," "retatrutide," and "what is GLP-3" has exploded over the past year, often outpacing searches for Ozempic itself. And a lot of the women asking are exactly the women we built this site for: in their late 40s and 50s, watching the weight settle around their middle in a way it never did before, and wondering whether this new thing everyone is talking about is the answer.

So let us do what we always try to do here: give you the honest, careful version. What "GLP-3" actually is. Why that name is a little misleading. How the drug behind the hype compares to the medications you already know. What the research says specifically for women in perimenopause and menopause, including the parts that should give you pause. And a frank warning about the gray market, because the same search data that brought you here is full of people trying to buy this drug from places they absolutely should not.

First, what is "GLP-3"? (And why that name is misleading)

Here is the thing nobody on TikTok will tell you: there is no hormone called GLP-3. It does not exist in your body. The name is internet shorthand, not science.

What people are actually talking about is a drug called retatrutide (you will also see it written as "reta" or its lab code, LY3437943), made by Eli Lilly. Retatrutide is a single molecule that switches on three different receptors at once: GLP-1, GIP, and glucagon. Because the medications before it hit one or two of those targets, people started counting them like sequels:

• "GLP-1" drugs (one target) — semaglutide, the medicine in Ozempic and Wegovy.
• The "dual" drugs (two targets, GLP-1 and GIP) — tirzepatide, the medicine in Mounjaro and Zepbound.
• The "triple" (three targets) — retatrutide, which the internet nicknamed "GLP-3."

It is a catchy way to remember the lineup, and we will use it here because it is what you are searching. But know that it is slang. (To make it more confusing, there genuinely is a hormone called GLP-2, and it has nothing to do with weight loss — it helps your gut lining grow. The naming collision is just a coincidence.) So when you see "GLP-3 retatrutide" or "is retatrutide a GLP-1," the accurate answer is: retatrutide is a triple receptor agonist that includes GLP-1 action, plus two more. "GLP-3" is a nickname for that triple-target design.

How retatrutide works: the triple agonist, in plain language

The drugs you already know mostly work by turning down appetite. GLP-1 and GIP signaling makes you feel full sooner, slows how fast your stomach empties, and quiets the food chatter in your brain. That is the "eat less" half of the equation, and it is powerful on its own.

Retatrutide adds a third lever: glucagon. Glucagon agonism is thought to nudge up your energy expenditure — loosely, the "burn more" side — and to push the liver to release stored fat for fuel. The idea is that combining "eat less" with "burn more" produces more total fat loss than appetite suppression alone. (One counterintuitive note for anyone who knows their physiology: glucagon usually raises blood sugar, yet in the trials retatrutide actually improved blood-sugar control, because the GLP-1 and GIP effects dominate.) You can read Lilly's own plain-language explanation of the mechanism here.

Is GLP-3 / retatrutide FDA approved? Can you even get it?

This is the single most important thing on this page, so we are going to be blunt: retatrutide is not FDA approved. As of mid-2026 it is still an investigational drug. The only legal way to take it is by enrolling in one of Lilly's clinical trials. Lilly says it directly — anything sold to consumers outside those trials is illegal, "with no way to verify its safety, purity, or dosing."

The Phase 3 program (called TRIUMPH) is reading out now. The first big obesity trial, TRIUMPH-1, reported results in May 2026, and the numbers were striking (more on those below). But a Phase 3 readout is not an approval. There is no published FDA filing date, and — importantly — the large heart-safety outcomes trial does not finish until around 2029. So even in the best case, retatrutide would launch before its long-term cardiovascular data is fully in.

What you can get today, by prescription, from a licensed clinician, are the medications that have already cleared that bar: semaglutide (Wegovy) and tirzepatide (Zepbound). (An oral semaglutide pill was also approved at the end of 2025.) If you are a woman who wants help with menopausal weight gain right now, those — not a vial of "GLP-3" from a website — are the real options to discuss with a provider.

How much weight do people actually lose on retatrutide?

The reason for all the noise is, frankly, the efficacy. In the Phase 2 obesity trial published in the New England Journal of Medicine in 2023, adults at the highest dose lost an average of 24.2% of their body weight at 48 weeks — and notably, that trial group averaged 48 years old and was about half women. The Phase 3 TRIUMPH-1 results in 2026 went further: about 28.3% average weight loss at 80 weeks at the top dose, with a longer-duration, higher-starting-weight subgroup reaching roughly 30%.

To put that in context against the medications you know — with the big caveat that these are separate trials, not a head-to-head race, so the comparison is directional only:

• Semaglutide (Wegovy): about 15% average weight loss (STEP 1 trial).
• Tirzepatide (Zepbound): about 21–22.5% (SURMOUNT-1 trial).
• Retatrutide ("GLP-3"): about 24% in Phase 2, ~28% in Phase 3.

One detail that matters for our readers: in the Phase 2 trial, women lost meaningfully more weight than men at the same doses. Retatrutide has also shown dramatic reductions in liver fat and promising results in a trial for knee osteoarthritis. The headline efficacy is real. But efficacy is only half of a medical decision — the other half is safety and fit, and that is where the conversation gets more nuanced for midlife women.

GLP-3 side effects and safety

The most common side effects are the ones you would expect from this class: nausea, vomiting, diarrhea, and constipation, mostly mild to moderate and concentrated during the weeks when the dose is being increased. In the Phase 2 trial, somewhere between 6% and 16% of people stopped the drug because of side effects, depending on dose.

A few things are more specific to retatrutide and worth knowing:

• Heart rate. Retatrutide raised resting heart rate in a dose-dependent way — up to roughly 9 beats per minute at the highest dose around the 24-week mark — before drifting back down later in the trial. Blood pressure actually fell. But the early trials excluded people with significant heart disease, which is exactly why that 2029 outcomes trial matters.
• A skin-sensation effect. A small but real number of people reported altered or heightened skin sensitivity, something seen more with retatrutide than with older drugs.
• A class warning. The whole GLP-1 family carries a boxed warning about a rare risk of thyroid C-cell tumors, and is not recommended for anyone with a personal or family history of medullary thyroid cancer or the genetic condition MEN 2. Pancreatitis and gallbladder problems are also known cautions for the class. Retatrutide has no FDA label yet, but given its GLP-1 component, expect these to apply.

The honest summary: the short-term safety looks broadly consistent with the rest of the class, but the long-term picture — heart, thyroid, pancreas, and what happens over many years — is genuinely not established yet.

What this means for women in perimenopause and menopause

Here is where it gets personal, because menopausal weight gain is not just "eating too much," and any honest article has to say so.

As estrogen declines through perimenopause, two things happen. Your metabolism slows, and your body changes where it stores fat — shifting it from the hips and thighs to the abdomen, as deep visceral fat around your organs. Across the menopause transition, visceral fat can roughly triple as a share of your total body fat, and the average woman gains around a pound and a half a year in midlife. The Cleveland Clinic has a good plain-English overview of why this happens. This is not a willpower failure. It is endocrinology.

That is also why medications in this class are so appealing to midlife women — they target appetite and metabolism, the exact systems that estrogen loss disrupts. And the data is encouraging: a large pooled analysis of tirzepatide found that menopausal women lost nearly as much weight as younger women (around 23% whether they were peri- or post-menopausal), reported by NewYork-Presbyterian. There is no menopause-specific analysis of retatrutide yet — an honest gap — but there is no reason to expect it would suddenly stop working for women in midlife.

The muscle and bone problem no one warns midlife women about

This is the section we most want you to read, because it is the one the hype skips.

When you lose weight rapidly on any of these drugs, not all of what you lose is fat. On average, roughly a quarter of the weight lost on incretin medications is lean mass — muscle — according to body-composition data from the tirzepatide trials (a substudy that was, tellingly, about three-quarters women with an average age in the mid-40s). For a 30-year-old that is a manageable trade-off. For a woman in menopause, it is a bigger deal, for two reasons:

• You are already losing muscle. Muscle mass declines naturally with age, and menopause accelerates it. Stacking drug-driven muscle loss on top of age- and estrogen-driven muscle loss raises the real risk of sarcopenia — the kind of muscle loss that erodes strength, metabolism, and independence.
• You are already losing bone. Estrogen withdrawal speeds bone loss, and rapid weight loss itself lowers bone density — more so after menopause. The evidence on whether GLP-1 drugs specifically help or hurt bone is genuinely mixed right now, so the responsible stance is monitoring, not panic.

None of this means these drugs are off-limits for menopausal women. It means that how you do it matters enormously. Adequate protein (often more than women are used to eating), consistent resistance training, weight-bearing exercise, and bone-density monitoring are not optional add-ons in midlife — they are what separates "lost fat, kept my strength" from "lost weight, got frail." That is also a conversation a good clinician will start with you, not one you should be navigating alone from a forum.

HRT and GLP-1 medications together: what the new research shows

This is the question we get most, and it is squarely in our wheelhouse: can you take hormone therapy and a GLP medication at the same time?

The early signal is intriguing. A 2026 retrospective study from the Mayo Clinic, published in The Lancet's women's-health journal, followed 120 postmenopausal women on tirzepatide. The women who were also on menopausal hormone therapy lost meaningfully more weight — on the order of 35% more — than those on the weight-loss medication alone. You can read Mayo's summary here. The proposed reason is that estrogen seems to enhance GLP-1's appetite-suppressing effect.

It is a genuinely exciting hint that the two therapies might work better as a pair than either does alone. But please hold it loosely: this was a small, retrospective, observational study — 120 women, looking backward — which can show an association but cannot prove cause. The authors themselves call for proper prospective trials. Standard considerations for whether HRT is right for you still apply. The takeaway is not "go combine them"; it is "this is a promising area, and it is one more reason to have both conversations — hormones and metabolic health — with a clinician who understands menopause." If you do not have one yet, that is exactly what our provider directory is for.

The "research peptide" trap: why buying GLP-3 online is dangerous

We have to talk about this, because the search data is loud and clear: alongside "what is retatrutide," people are searching "retatrutide for sale," "where to buy," and "dosage calculator." Here is our flat, unhedged advice: do not buy retatrutide from a peptide website, and do not self-inject it.

Because retatrutide is not approved, gray-market sellers ship powder vials labeled "for research purposes only" or "not for human consumption" to dodge the law, then quietly point buyers toward influencer doses and online calculators. The FDA has explicitly called that labeling a sham, warning companies that "falsely labeled" these products when "the evidence demonstrates these products are actually intended to be used as drugs for humans" (FDA guidance). The dangers are not theoretical:

• Dosing catastrophes. With analogous compounded GLP-1 products, the FDA has documented patients accidentally taking 5 to 20 times the intended dose because of self-measurement and unit confusion.
• No quality control. There is no assurance of sterility, purity, or potency. Vials may contain contaminants, the wrong amount of drug, or not what is on the label.
• No medical supervision. No one is watching for pancreatitis, dangerous dehydration, or the very muscle-and-bone loss we just warned you about — all of which matter more, not less, in midlife.

Eli Lilly puts it plainly: illicit products "may contain unknown ingredients, harmful contaminants and impurities." Saving money on a vial is not worth the risk to a body that is already navigating enough change. If cost is the barrier — and for many women it is — the answer is a frank conversation with a provider about approved options, savings programs, and what your insurance covers, not a syringe from a stranger.

What to do if you are a woman considering a GLP medication

Pulling it together, here is the grounded path:

• Treat "GLP-3" as a preview, not a product. Retatrutide is the most powerful weight-loss drug in development, but it is not available legally, and it will not be for some time. Watch the space — do not chase it.
• Start with the approved options. If menopausal weight gain is affecting your health and your life, semaglutide and tirzepatide are real, prescribable, monitored medications today. They work well in menopausal women.
• Protect your muscle and bone. Whatever you take, pair it with protein and resistance training, and ask about a bone-density baseline. In midlife this is the difference-maker.
• Have the hormone conversation too. The emerging research on HRT plus GLP medications is one more reason to see a clinician who treats menopause comprehensively, not just one symptom at a time.
• Do not buy peptides online. Full stop.

The bottom line

"GLP-3" is the buzzy nickname for retatrutide, a triple-agonist drug that produces the largest weight loss yet seen in trials — and that genuinely could matter for women fighting the metabolic shift of menopause. But it is still investigational, the long-term safety is unproven, the muscle-and-bone trade-offs hit midlife women hardest, and the online "research peptide" version is dangerous. The exciting, on-label news for women right now is not the drug you cannot legally buy — it is the growing evidence that treating menopause well, hormones included, and pairing approved medications with strength and protein, is what actually helps women feel like themselves again. That is a plan you can start safely, with a real provider, this month.